Drug Discovery for Kinetoplastid Diseases: Future Directions.

Srinivasa PS Rao; Michael P Barrett; Glenn Dranoff; Christopher J Faraday; Claudio R Gimpelewicz; Asrat Hailu; Catherine L Jones; John M Kelly ORCID logo; Janis K Lazdins-Helds; Pascal Mäser; +9 more... Jose Mengel; Jeremy C Mottram ORCID logo; Charles E Mowbray; David L Sacks; Phillip Scott; Gerald F Späth; Rick L Tarleton; Jonathan M Spector; Thierry T Diagana; (2019) Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS INFECTIOUS DISEASES, 5 (2). pp. 152-157. ISSN 2373-8227 DOI: 10.1021/acsinfecdis.8b00298
Copy

Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.


picture_as_pdf
Rao-etal-2018-Drug-discovery-for-Kinetoplastid-diseases.pdf
subject
Published Version
copyright
Available under Copyright the publishers

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads